A comparison of ELT and SLT

Article

A study by Italian researchers, the results of which have been published online by Eye, has found that both excimer laser trabeculotomy (ELT) and selective laser trabeculoplasty (SLT) are both equally effective treatment options for primary open angle glaucoma.

A study by Italian researchers, the results of which have been published online by Eye, has found that both excimer laser trabeculotomy (ELT) and selective laser trabeculoplasty (SLT) are both equally effective treatment options for primary open angle glaucoma (POAG) refractory to medical therapy.

Silvia Babighian and colleagues from St Antonio Hospital in Padova, Italy sought to compare the safety and efficacy of ELT and SLT as a treatment for patients with POAG over a 24 month follow-up period. The prospective, randomized study consisted of 30 consecutive eyes assigned randomly to receive either of the treatments. ELT was performed with the XeCl excimer laser with an emission wavelength of 308 nm, with eight laser spots equally distributed over the anterior trabeculum. The SLT procedures were carried out with a frequency doubled q-switched neodymium : yytrium-aluminum-garnet laser. Approximately 50 adjacent laser spots were distributed over 180° of the trabecular meshwork. Procedure success was defined as a ≥20% reduction in IOP.

After 24 months, success in the ELT group was 53.3% and 40% in the SLT group. Mean IOP decreased 25.0±1.9 to 17.6±2.2 mmHg and from 23.9±0.9 to 19.1±1.8 mmHg in the ELT and SLT groups, respectively.

Babighian and colleagues were able to conclude that both techniques are effective in treating POAG.

Click here for full abstract.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.